Pressure On Opill Price From Lawmakers, Health Advocates, Not From Marketplace Competition
Pressure from members of Congress and public and reproductive health advocacy groups will continue for making Opill’s price affordable to consumers from all income levels, but competition won’t affect the price for three years.
You may also be interested in...
All nine present voting members of Germany's Expert Committee for Prescription rejected Perrigo's application to switch its progestogen-only contraceptive pill (desogestrel 75μg) from Rx to OTC status.
Shiseido, L’Oreal and The Estee Lauder Companies are preparing to announce earnings results for the final three months of 2023, and all are expected to report headwinds that held back performance in China. Analysts anticipate a strong fourth quarter from Coty, which has been largely insulated from the ups and downs of the Chinese market in recent years.
Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.